• Loading stock data...
Est. 2004

Wednesday 03/6/2019

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More


  • 2:42 PM

    Cannabics patent granted with enabling technology to personalize Cannabinoid diagnostics and treatment for Cancer patients PR Newswire TEL AVIV, Israel and BETHESDA, Maryland, April 18, 2018 TEL AVIV, Israel and BETHESDA, Maryland, April 18, 2018 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in cannabinoid diagnostics for the personalized treatment of cancer, today announced the receipt of a Notice of Allowance from The Patent Office of the State of Israel. The Patent Office intends to grant Cannabics the patent for its method of high throughput screening of

    Read more
  • 11:55 AM

    TEL-AVIV, Israel, Nov. 28, 2017, CNBX, /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids. The new license will enable the company to continue our vision of developing an ecosystem for creation of diagnostic tools and bringing to the market diagnostic services for cancer patients who are medicated with cannabis. Our forward looking plan encompasses a synergy between HTS (High Throughput

    Read more
  • 1:38 PM

    NEW YORK, Oct. 05, 2017, AXIM, (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech), (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/982,610, a patent that claims the use of an ophthalmic solution comprising cannabinoids for the treatment of glaucoma and symptomatic relief of conjunctival inflammation. A Notice of Allowance is issued after the USPTO makes a determination that a

    Read more
  • 12:17 PM

    Aug 01, 2017, ETST, OTC Disclosure & News Service – Hollywood, FL, Aug. 01, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotechnology company that operates in the fields of hemp cannabinoid, nutraceutical, pharmaceutical, and medical device research and development, announces that it has signed an agreement with the Centre de Développement Bioalimentaire du Québec (CDBQ), a major force in the agro-food industry in Canada. CDBQ to take ETST products from

    Read more
  • 3:05 PM

    TEL AVIV, Israel, July 24, 2017, CNBX, /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today announced it has established a Genetic lab that will develop diagnostic tools based on human genome, tumor genetics and cannabinoids. The company recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Moran has a PhD in Virology and MSc in clinical pharmacology with vast experience in conceptualizing and executing pharmacological research. Dr. Eyal Ballan, Co-founder and CTO, said: “Our mission is to commercialize

    Read more
  • 3:17 PM

    LAS VEGAS, May 23, 2017, GBLX, /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the filing of its latest patent application by its wholly-owned subsidiary, Growblox Life Sciences, LLC for the treatment of chronic pain and heart therapies based on myrcene-containing complex mixtures (“MCCM”). The current US opioid epidemic, along with growing public and government concern regarding opioid abuse, makes new pain treatments a promising field of research and development. Our novel pain formulations are also substantially free of

    Read more
Public Wire Banner